TheraSphere Y-90 Glass Microspheres System
BOSTON SCIENTIFIC CORPORATION · Decision date Oct 13, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-10-13 for PMA supplement P200029/S015, submitted by Boston Scientific Corporation under a 30-Day Notice for a process change involving a manufacturer, sterilizer, packager or supplier. The supplement covers the TheraSphere Y-90 Glass Microspheres System, a radionuclide microsphere device classified under product code NAW in radiology.
The recorded scope is narrow: reinstatement of previously approved manufacturing Room 1531 at BWXT Medical Limited for routine manufacture of TheraSphere Yttrium-90 Glass Microspheres. This is a supplement action on an existing approval, not a new approval of the whole system, and the source does not describe clinical performance, patient selection or labeling changes. The source also lists no supporting documents, so the review basis and any conditions tied to the reinstatement remain unknown.
FDA approval order statement
approval for the reinstatement of previously approved manufacturing Room 1531 at BWXT Medical Limited for routine manufacture of TheraSphere Yttrium-90 Glass Microspheres.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Radiology
- Decision date
- Oct 13, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200029/S015
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- NAW
- Decision code
- OK30
- Decision date
- Oct 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Microspheres radionuclide.
- Applicant
- Boston Scientific Corporation
- Product code
- NAW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200029. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200029 · Original PMA
TheraSphere
P200029/S015 received
Application receipt date recorded by FDA.
P200029/S015 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TheraSphereP200029 | BOSTON SCIENTIFIC CORPORATION | PMA approval | Mar 17, 2021 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 300 Boston Scientific Way, Marborough, MA, 01752
Sources and methodology
- Original FDA record: P200029/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records